Rosiglitazone Is Associated with Sharp Lipid Irregularity

JANUARY 01, 2005

Researchers in the United Kingdom found 3 cases linking lipid abnormalities with rosiglitazone. The study showed that treatment with rosiglitazone might cause an acute decrease in high-density lipoprotein (HDL; "good") cholesterol and an increase in fasting triglycerides. Reporting in Diabetes Care (November 2004), the researchers said that the 3 participants had type 2 diabetes and high cholesterol and were being treated with rosiglitazone. The results of the study indicated that rosiglitazone was temporally related to a drastic decline in HDL cholesterol.

Once the drug was stopped, the patients had a rapid return of HDL cholesterol to pretreatment levels. All 3 patients had a "striking improvement" in blood sugar control with rosiglitazone treatment even with the abnormal cholesterol response. The researchers noted that the mechanism of rosiglitazone-induced cholesterol abnormalities remains to be determined. Although the cholesterol problem was rare, the researchers recommended that a full lipid profile, including HDL cholesterol, be taken prior to beginning rosiglitazone and similar drugs and again 3 months later.



SHARE THIS SHARE THIS
0

Conference Coverage from ASHP Summer 2017 

Four years after they first launched the Summer Meetings in Minneapolis, Minn., the ASHP 2017 Summer Meetings and Exhibition was in Minneapolis once again.  

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.